explore -WSS

explore

author：knowledge 2025-09-28 21:05:29 - browse：189

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA approves first blood sugar monitor without finger pricks

knowledge

WSS

Doctors have an ethical obligation to be advocates

FDA warns medical device makers about rise in fabricated data

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Sophia Smith scores twice for US in in 3

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

explore

explore

leisure time

Bright Health sells Medicare Advantage business to Molina

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

New air purifier tech could be key to improving indoor air quality

4 missing after record

Psychedelics group wrestles with new pharma identity

FDA approves first blood sugar monitor without finger pricks

Sports medicine is finally prioritizing gender equality

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

The cancer drug shortage isn’t new — and neither are the solutions

My chronic pain journey would have been easier knowing 5 things % STAT

hotspot

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

How a key Senate committee is planning to regulate PBMs

Where does female orgasm come from? Scientists think they know

New CMS data security rules will hurt Medicare, Medicaid research

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Novartis develops a rapidly manufactured CAR

explore

knowledge

entertainment

focus